Zhaoling Meng, AVP, Sanofi, will discuss the global pharma organisations' use of AI to develop and implement digital twins in clinical trials.

Key Discussion Points:

• Simulating Patient Responses: How digital twins are used to predict and model patient reactions to treatments.
• Personalizing Treatment: The application of digital twins for tailoring treatment plans to individual patient profiles
• Optimizing Trial Protocols: Utilising digital twins to improve the efficiency of clinical trial design.

As AI continues to revolutionise healthcare, critical questions remain about its global impact, accessibility, and long-term market sustainability. Despite rapid advancements, no AI-discovered drug has yet passed Phase 3 clinical trials—how close are we to this breakthrough, and what challenges must be overcome?This closing panel brings together leading experts to explore the future of AI-driven therapeutics, the evolving biotech-pharma relationship, and strategies for ensuring equitable access to AI-powered healthcare innovations.

Key topics include:

• The Road to AI Drug Approval: What hurdles remain before AI-discovered drugs reach the market?

• Funding & Investment: How can we secure sustainable funding for AI-driven drug development?

• Bridging the Accessibility Gap: Ensuring AI-powered healthcare benefits reach global populations